Experienced in Acute Mountain Sickness

Dr. Michael T. Byrne

Hematology | Hematology Oncology
Tennessee Oncology PLLC
2004 Hayes St, Suite 350, 
Nashville, TN 
Accepting New Patients
Offers Telehealth
Experienced in Acute Mountain Sickness
Tennessee Oncology PLLC
2004 Hayes St, Suite 350, 
Nashville, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Byrne is a Hematologist and a Hematologist Oncology provider in Nashville, Tennessee. Dr. Byrne is rated as an Experienced provider by MediFind in the treatment of Acute Mountain Sickness. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Byrne is currently accepting new patients.

His clinical research consists of co-authoring 10 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Hematology Oncology
Licenses
Internal Medicine in OH
Hospital Affiliations
Ascension Saint Thomas Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
US Health and Life
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

TENNESSEE ONCOLOGY PLLC
2004 Hayes St, Suite 350, Nashville, TN 37203

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase II Study of Ruxolitinib Pre-, During- and Post-Hematopoietic Stem Cell Transplantation for Patients With Primary or Secondary Myelofibrosis.
A Phase II Study of Ruxolitinib Pre-, During- and Post-Hematopoietic Stem Cell Transplantation for Patients With Primary or Secondary Myelofibrosis.
Enrollment Status: Completed
Publish Date: July 29, 2025
Intervention Type: Drug
Study Drug: Ruxolitinib
Study Phase: Phase 2
Phase II Study of Maintenance Ruxolitinib After Allogeneic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) in Complete Remission
Phase II Study of Maintenance Ruxolitinib After Allogeneic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) in Complete Remission
Enrollment Status: Active_not_recruiting
Publish Date: July 14, 2025
Intervention Type: Drug
Study Drug: Ruxolitinib
Study Phase: Phase 2
An Investigator-Sponsored Phase Ib Trial of Venetoclax and SINE: Selective Inhibition of Nuclear Export in Patients with High Risk Hematologic Malignancies
An Investigator-Sponsored Phase Ib Trial of Venetoclax and SINE: Selective Inhibition of Nuclear Export in Patients with High Risk Hematologic Malignancies
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drugs: Venetoclax, Selinexor
Study Phase: Phase 1
A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)
A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)
Enrollment Status: Terminated
Publish Date: January 30, 2024
Intervention Type: Biological, Drug
Study Drug: Flotetuzumab
Study Phase: Phase 1/Phase 2
A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of KTE-X19 in Adult Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of KTE-X19 in Adult Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Enrollment Status: Terminated
Publish Date: November 18, 2023
Intervention Type: Biological, Drug
Study Drugs: Brexucabtagene Autoleucel, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
Ph 1 Study of Escalating Single & Multiple Doses of Mana 312 (Multi Tumor-Associated Antigen T Cells) Administered to Adult Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplant
Ph 1 Study of Escalating Single & Multiple Doses of Mana 312 (Multi Tumor-Associated Antigen T Cells) Administered to Adult Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplant
Enrollment Status: Terminated
Publish Date: June 18, 2023
Intervention Type: Biological
Study Drug: Mana 312
Study Phase: Phase 1
A Phase 1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells After Partially Mismatched, Related, T Cell-Depleted HSCT (Hematopoietic Stem Cell Transplant)
A Phase 1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells After Partially Mismatched, Related, T Cell-Depleted HSCT (Hematopoietic Stem Cell Transplant)
Enrollment Status: Active_not_recruiting
Publish Date: July 12, 2022
Intervention Type: Biological, Drug, Procedure
Study Drugs: BPX-501, Rimiducid
Study Phase: Phase 1/Phase 2
A Phase I Study of Donor BPX-501 T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant
A Phase I Study of Donor BPX-501 T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant
Enrollment Status: Active_not_recruiting
Publish Date: July 12, 2022
Intervention Type: Biological, Drug
Study Drugs: BPX-501, Rimiducid
Study Phase: Phase 1
View 7 Less Clinical Trials

10 Total Publications

Key Challenges in CAR T-Cell Therapy Access in Community Oncology.
Key Challenges in CAR T-Cell Therapy Access in Community Oncology.
Journal: JAMA oncology
Published: March 06, 2025
Similar Doctors
Distinguished in Acute Mountain Sickness
Dr. Jack W. Erter
Hematology Oncology | Hematology | Oncology
Distinguished in Acute Mountain Sickness
Dr. Jack W. Erter
Hematology Oncology | Hematology | Oncology

Tennessee Oncology PLLC

397 Wallace Rd, Suite C201, 
Nashville, TN 
 (6.8 miles away)
615-333-2481
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jack Erter is a Hematologist Oncology specialist and a Hematologist in Nashville, Tennessee. Dr. Erter is rated as a Distinguished provider by MediFind in the treatment of Acute Mountain Sickness. His top areas of expertise are Iron Deficiency Anemia, Childhood Iron Deficiency Anemia, Familial Colorectal Cancer, and Acute Mountain Sickness. Dr. Erter is currently accepting new patients.

Distinguished in Acute Mountain Sickness
Dr. Tamjeed Ahmed
Hematology Oncology | Hematology | Oncology
Distinguished in Acute Mountain Sickness
Dr. Tamjeed Ahmed
Hematology Oncology | Hematology | Oncology

Tennessee Oncology PLLC

250 25th Ave N, 
Nashville, TN 
 (0.6 miles away)
615-320-5090
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Tamjeed Ahmed is a Hematologist Oncology specialist and a Hematologist in Nashville, Tennessee. Dr. Ahmed is rated as a Distinguished provider by MediFind in the treatment of Acute Mountain Sickness. His top areas of expertise are Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), Lung Cancer, and Iron Deficiency Anemia. Dr. Ahmed is currently accepting new patients.

Distinguished in Acute Mountain Sickness
Dr. Nnamdi I. Eze
Hematology Oncology | Hematology | Oncology
Distinguished in Acute Mountain Sickness
Dr. Nnamdi I. Eze
Hematology Oncology | Hematology | Oncology

Tennessee Oncology PLLC

Shelbyville, TN 
 (51.3 miles away)
931-680-0602
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nnamdi Eze is a Hematologist Oncology specialist and a Hematologist in Shelbyville, Tennessee. Dr. Eze is rated as a Distinguished provider by MediFind in the treatment of Acute Mountain Sickness. His top areas of expertise are Iron Deficiency Anemia, Hemochromatosis, Childhood Iron Deficiency Anemia, and Acute Mountain Sickness. Dr. Eze is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Byrne's expertise for a condition
ConditionClose
    View All 21 Advanced Conditions
    View All 58 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile